{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:59Z","timestamp":1790659259998,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.metabol.2025.156187","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:06:40Z","timestamp":1741637200000},"page":"156187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4506-0472","authenticated-orcid":false,"given":"Mariana","family":"de Moura de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0788-130X","authenticated-orcid":false,"given":"Beatriz Ximenes","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-5616","authenticated-orcid":false,"given":"Maria Luiza Rodrigues","family":"Defante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7345-0751","authenticated-orcid":false,"given":"Beatriz Austreg\u00e9lio","family":"de Athayde de Hollanda Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2237-2799","authenticated-orcid":false,"given":"Ot\u00e1vio Cosendey","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7974-0068","authenticated-orcid":false,"given":"Vit\u00f3ria Martins","family":"Priz\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Romaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.metabol.2025.156187_bb0005","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.metabol.2025.156187_bb0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"371","key":"10.1016\/j.metabol.2025.156187_bb0015","article-title":"Management of hypertriglyceridemia","author":"Simha","year":"2020","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.metabol.2025.156187_bb0020","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.metabol.2025.156187_bb0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.metabol.2025.156187_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.metabol.2025.156187_bb0035","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1038\/s41598-017-05163-w","article-title":"A novel role for RAR\u03b1 agonists as apolipoprotein CIII inhibitors identified from high throughput screening","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.metabol.2025.156187_bb0040","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.metabol.2025.156187_bb0045","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.metabol.2025.156187_bb0050","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.metabol.2025.156187_bb0055","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.metabol.2025.156187_bb0060","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.metabol.2025.156187_bb0065","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for Severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.metabol.2025.156187_bb0070","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.metabol.2025.156187_bb0075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.metabol.2025.156187_bb0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2025.156187_bb0085","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2025.156187_bb0090","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12020-022-03025-8","article-title":"Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis","volume":"76","author":"Cheng","year":"2022","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.metabol.2025.156187_bb0095","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.eprac.2024.08.013","article-title":"Safety and efficacy of the novel RNA interference therapies for hypertriglyceridemia and mixed hyperlipidemia management: a systematic review and meta-analysis","volume":"30","author":"Kamrul-Hasan","year":"2024","journal-title":"Endocr Pract"},{"issue":"10263","key":"10.1016\/j.metabol.2025.156187_bb0100","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","article-title":"Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort","volume":"396","author":"Mortensen","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.metabol.2025.156187_bb0105","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.118.034273","article-title":"Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease","volume":"138","author":"Abdullah","year":"2018","journal-title":"Circulation"},{"issue":"32","key":"10.1016\/j.metabol.2025.156187_bb0110","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.metabol.2025.156187_bb0115","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.metabol.2025.156187_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.metabol.2025.156187_bb0125","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"343","key":"10.1016\/j.metabol.2025.156187_bb0130","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2025.156187_bb0135","author":"Rohatgi"},{"issue":"343","key":"10.1016\/j.metabol.2025.156187_bb0140","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.metabol.2025.156187_bb0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11883-023-01080-8","article-title":"APOC-III: a gatekeeper in controlling triglyceride metabolism","volume":"25","author":"Giammanco","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.metabol.2025.156187_bb0150","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"19","key":"10.1016\/j.metabol.2025.156187_bb0155","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1161\/CIRCULATIONAHA.111.056986","article-title":"Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease","volume":"124","author":"Mendivil","year":"2011","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.metabol.2025.156187_bb0160","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"10.1016\/j.metabol.2025.156187_bb0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3949\/ccjm.87a.19078","article-title":"ACC\/AHA lipid guidelines: personalized care to prevent cardiovascular disease","volume":"87","author":"Reiter-Brennan","year":"2020","journal-title":"CCJM"},{"issue":"1","key":"10.1016\/j.metabol.2025.156187_bb0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.metabol.2025.156187_bb0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.metabol.2025.156187_bb0180","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.metabol.2025.156187_bb0185","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.metabol.2025.156187_bb0190","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"issue":"9500","key":"10.1016\/j.metabol.2025.156187_bb0195","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.metabol.2025.156187_bb0200","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.metabol.2025.156187_bb0205","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.metabol.2025.156187_bb0210","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.metabol.2025.156187_bb0215","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.metabol.2025.156187_bb0220","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"issue":"9753","key":"10.1016\/j.metabol.2025.156187_bb0225","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.metabol.2025.156187_bb0230","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.metabol.2025.156187_bb0235","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.metabol.2025.156187_bb0240","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction","volume":"307","author":"Di Angelantonio","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2025.156187_bb0245","series-title":"New approaches for treatment of hypertriglyceridemia","author":"Mikhail","year":"2024"},{"issue":"6","key":"10.1016\/j.metabol.2025.156187_bb0250","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"10.1016\/j.metabol.2025.156187_bb0255","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T20:37:00Z","timestamp":1743971820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":51,"alternative-id":["S0026049525000563"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156187","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156187"}}